- Membership Level
MorphoSys is a clinical stage biopharmaceutical company headquartered in Munich, Germany. MorphoSys is dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Temfya, marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys’s antibody technology to receive regulatory approval. The Company’s most advanced proprietary product candidate, MOR20B, has been granted US FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
The fully-owned MorphoSys US Inc., located in Boston, is the US subsidiary of MorphoSys and started operations in July 2018. the initial focus of MorphoSys US Inc. is to establish a strong US footprint for MorphoSys and to build the Company’s commercial capabilities in preparation for the planned commercialization of MOR20B following FDA approval.